1ZLB.MU Stock Analysis
1Z
Uncovered
Zai Lab Ltd is uncovered by Eyestock quantitative analysis.
Rating
To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.
Low score
Zai Lab Ltd. is a biopharmaceutical company, which engages in the developing and commercializing therapies that address medical conditions with unmet needs in oncology, autoimmune disorders, infectious diseases, and neuroscience. The company is headquartered in Shanghai, Shanghai. The company went IPO on 2020-09-28. The firm is focused on discovering or licensing, developing and commercializing proprietary therapeutics that address areas of large unmet medical need in the China market, including oncology, autoimmune and infectious diseases fields. The firm has a broad pipeline of proprietary drug candidates that range from discovery stage to late-stage clinical programs. These include Niraparib (ZL-2306), ZL-2103, ZL-1101 and others.